{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:36:57Z","timestamp":1794659817609,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202997"],"award-info":[{"award-number":["82202997"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072562"],"award-info":[{"award-number":["82072562"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1038\/s41591-023-02461-x","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T12:01:51Z","timestamp":1690200111000},"page":"2079-2086","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial"],"prefix":"10.1038","volume":"29","author":[{"given":"Si-Yang Maggie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-8923","authenticated-orcid":false,"given":"Xue-Wu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Rong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiu-Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-2809","authenticated-orcid":false,"given":"Chong-Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Si","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. E.","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6504-6083","authenticated-orcid":false,"given":"Chang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bu-Hai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Dong","family":"Cang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0974-4036","authenticated-orcid":false,"given":"Yangqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-176X","authenticated-orcid":false,"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"2461_CR1","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biology Evaluation and Research. Enhancing the Diversity of Clinical Trial Populations\u2014Eligibility Criteria, Enrollment Practices, and Trial Designs. Guidance for Industry (2022); https:\/\/www.fda.gov\/media\/127712\/download"},{"key":"2461_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-022-01775-6","volume":"28","author":"BT Li","year":"2022","unstructured":"Li, B. T. et al. Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. Nat. Med. 28, 620\u2013626 (2022).","journal-title":"Nat. Med."},{"key":"2461_CR3","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/j.cllc.2022.05.009","volume":"23","author":"SM Liu","year":"2022","unstructured":"Liu, S. M. et al. Biomarker-driven studies with multi-targets and multi-drugs by next-generation sequencing for patients with non-small-cell lung cancer: an open-label, multi-center, phase II adaptive umbrella trial and a real-world observational study (CTONG1702&CTONG1705). Clin. Lung Cancer 23, e395\u2013e399 (2022).","journal-title":"Clin. Lung Cancer"},{"key":"2461_CR4","unstructured":"Real-world evidence. US Food and Drug Administration https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence (2022)."},{"key":"2461_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/431525b","volume":"431","author":"P Stephens","year":"2004","unstructured":"Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525\u2013526 (2004).","journal-title":"Nature"},{"key":"2461_CR6","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/1759-7714.13419","volume":"11","author":"X-W Wei","year":"2020","unstructured":"Wei, X.-W. et al. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer. Thorac. Cancer 11, 1512\u20131521 (2020).","journal-title":"Thorac. Cancer"},{"key":"2461_CR7","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","volume":"31","author":"J Mazi\u00e8res","year":"2013","unstructured":"Mazi\u00e8res, J. et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 31, 1997\u20132003 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2461_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.21.01455","volume":"40","author":"J Mazieres","year":"2022","unstructured":"Mazieres, J. et al. Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non-small-cell lung cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 Trial. J. Clin. Oncol. 40, 719\u2013728 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2461_CR9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","volume":"26","author":"MG Kris","year":"2015","unstructured":"Kris, M. G. et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann. Oncol. 26, 1421\u20131427 (2015).","journal-title":"Ann. Oncol."},{"key":"2461_CR10","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.jtho.2018.07.093","volume":"13","author":"S Peters","year":"2018","unstructured":"Peters, S. et al. Activity of afatinib in heavily pretreated patients with ERBB2 mutation-positive advanced NSCLC: findings from a global named patient use program. J. Thorac. Oncol. 13, 1897\u20131905 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"2461_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.21.01323","volume":"40","author":"X Le","year":"2022","unstructured":"Le, X. et al. Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial. J. Clin. Oncol. 40, 710\u2013718 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2461_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1158\/1078-0432.CCR-21-2936","volume":"28","author":"Z Song","year":"2022","unstructured":"Song, Z. et al. Pyrotinib in patients with HER2-amplified advanced non-small cell lung cancer: a prospective, multicenter, single-arm trial. Clin. Cancer Res. 28, 461\u2013467 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2461_CR13","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","volume":"36","author":"BT Li","year":"2018","unstructured":"Li, B. T. et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J. Clin. Oncol. 36, 2532\u20132537 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2461_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","volume":"10","author":"BT Li","year":"2020","unstructured":"Li, B. T. et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov. 10, 674\u2013687 (2020).","journal-title":"Cancer Discov."},{"key":"2461_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li, B. T. et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N. Engl. J. Med. 386, 241\u2013251 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2461_CR16","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.19.00108","volume":"37","author":"F Ma","year":"2019","unstructured":"Ma, F. et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and\/or trastuzumab: a randomized, phase II study. J. Clin. Oncol. 37, 2610\u20132619 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2461_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 351\u2013360 (2021).","journal-title":"Lancet Oncol."},{"key":"2461_CR18","doi-asserted-by":"publisher","first-page":"PD8-08","DOI":"10.1158\/1538-7445.SABCS21-PD8-08","volume":"82","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. Abstract PD8-08: pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): a randomized, double-blind, multicenter, phase 3 study. Cancer Res. 82, PD8-08 (2022).","journal-title":"Cancer Res."},{"key":"2461_CR19","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1200\/JCO.20.00297","volume":"38","author":"C Zhou","year":"2020","unstructured":"Zhou, C. et al. Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase II study. J. Clin. Oncol. 38, 2753\u20132761 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2461_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02245-z","volume":"20","author":"Z Song","year":"2022","unstructured":"Song, Z. et al. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. BMC Med. 20, 42 (2022).","journal-title":"BMC Med."},{"key":"2461_CR21","first-page":"1","volume":"42","author":"JH Benbow","year":"2022","unstructured":"Benbow, J. H. et al. Increasing inclusiveness of patient-centric clinical evidence generation in oncology: real-world data and clinical trials. Am. Soc. Clin. Oncol. Educ. Book 42, 1\u201311 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"2461_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature15819","volume":"526","author":"AV Biankin","year":"2015","unstructured":"Biankin, A. V., Piantadosi, S. & Hollingsworth, S. J. Patient-centric trials for therapeutic development in precision oncology. Nature 526, 361\u2013370 (2015).","journal-title":"Nature"},{"key":"2461_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41586-020-2481-8","volume":"583","author":"G Middleton","year":"2020","unstructured":"Middleton, G. et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature 583, 807\u2013812 (2020).","journal-title":"Nature"},{"key":"2461_CR24","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.jtho.2019.06.027","volume":"14","author":"MJ Edelman","year":"2019","unstructured":"Edelman, M. J. et al. SWOG S1400C (NCT02154490)\u2014a phase II study of palbociclib for previously treated cell cycle gene alteration-positive patients with stage IV squamous cell lung cancer (Lung-MAP substudy). J. Thorac. Oncol. 14, 1853\u20131859 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"2461_CR25","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1158\/1078-0432.CCR-20-3857","volume":"27","author":"RD Harvey","year":"2021","unstructured":"Harvey, R. D. et al. Impact of broadening trial eligibility criteria for patients with advanced non-small cell lung cancer: real-world analysis of select ASCO-Friends recommendations. Clin. Cancer Res. 27, 2430\u20132434 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2461_CR26","doi-asserted-by":"publisher","first-page":"e31917","DOI":"10.2196\/31917","volume":"23","author":"SW Wan","year":"2021","unstructured":"Wan, S. W. et al. A theory-based, multidisciplinary approach to cocreate a patient-centric digital solution to enhance perioperative health outcomes among colorectal cancer patients and their family caregivers: development and evaluation study. J. Med. Internet Res. 23, e31917 (2021).","journal-title":"J. Med. Internet Res."},{"key":"2461_CR27","unstructured":"FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer. US Food and Drug Administration https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung (2022)."},{"key":"2461_CR28","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin, M. et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J. Thorac. Oncol. 14, 1784\u20131793 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"2461_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26806-7","volume":"12","author":"S-Y Liu","year":"2021","unstructured":"Liu, S.-Y. et al. Genomic signatures define three subtypes of EGFR-mutant stage II\u2013III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nat. Commun. 12, 6450 (2021).","journal-title":"Nat. Commun."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02461-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02461-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02461-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T10:18:21Z","timestamp":1692094701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02461-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2461"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02461-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"11 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of this article initially published, the Abstract did not list the ClinicalTrials.gov identifiers NCT03574402 and NCT03605602, which are now amended in the HTML and PDF versions of the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.-L.W. reports getting honoraria from AstraZeneca, Lily, Roche, Pfizer, Boehringer Ingelheim, MSD Oncology, Bristol-Myers Squibb\/China, Hengrui Pharmaceutical and BeiGene Beijing; consulting and advisory services for AstraZeneca, Roche and Takeda; and getting research funding from Roche, Boehringer Ingelheim, Pfizer and BMS. Q.Z. reports honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, MSD, Pfizer, Roche and Sanofi outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}